Phase III clinical trial - Appareil pulmonaire

CANOPY-1
Appareil pulmonaire
Ouvert depuis le: 04.23.2019
Site: Paris
Public cible
Adulte
A randomized, double-blind, placebo-controlled, phase III;study evaluating the efficacy and safety of pembrolizumab;plus platinum-based doublet chemotherapy with or without;canakinumab as first line therapy for locally advanced or;metastatic non-squamous and squamous non-small cell;lung cancer subjects (CANOPY-1)
Description de l'essai

The rationale for treating subjects with canakinumab is based upon the key role;inflammation plays in the development and spread of NSCLC and the ability of;canakinumab to suppress elevated C-reactive protein (CRP), which correlates with;NSCLC stage. CANTOS, a cardiovascular study demonstrated that not only was the;composite endpoints of stroke and myocardial infarction decreased by canakinumab,;but also the occurrence of and mortality from NSCLC was decreased. Additionally CRP;suppression correlated with responses in NSCLC patients treated with atezolizumab.